Deed poll

EQS-News: Steinhoff International Holdings N.V. in liquidatie: SHAREHOLDER CVR RECORD DATE AND REGISTRATION

Retrieved on: 
Wednesday, August 23, 2023
JSE Limited, Date, Frankfurt Stock Exchange, JSE, FSE, CVR, Computershare, Contingent value rights, Deed poll, News, Security (finance), Cryptocurrency

Steinhoff International Holdings N.V. in liquidatie (“SIHNV” or the “Company”) provides the following update regarding the shareholder Contingent Value Right (“CVR”) Record Date and the registration process.

Key Points: 
  • Steinhoff International Holdings N.V. in liquidatie (“SIHNV” or the “Company”) provides the following update regarding the shareholder Contingent Value Right (“CVR”) Record Date and the registration process.
  • Unless otherwise defined, capitalised terms used in this announcement will have the meaning assigned to them in the CVR Deed Poll available on the Company’s website (the “CVR Deed”).
  • The Company, together with Steinhoff Topco B.V., hereby notifies shareholders that the CVR Record Date for shareholders is Thursday, 31 August 2023.
  • The date on which beneficiaries of Securities listed on the FSE must be recorded as such in the register of PLC Nominees (Pty) Limited to register for CVR’s is the Record Date.

VEON issues amended Scheme

Retrieved on: 
Wednesday, January 11, 2023
United Kingdom, Euronext Amsterdam, Put, Personal Information Agent, Deed, Trustee, Information, Deed poll, Union, Element, Standstill period, Intermediary, Eligibility, Chair, DTC, VEON, Moelis & Company, Republic, Section 4, Appendix, Part, NSD, PJSC VimpelCom, Belarus, Creditor, Explanation, LLP, Note, Russia, United Nations, USD, Exercise, Bermuda, First Nations in Ontario, PJSC, Calendar, Constitutional amendment, Court, Cryptocurrency, Audit, Security (finance), Proxy, Scheme

Amsterdam, Netherlands, 11 January 2023 23:50 CET: VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON) (“VEON” or, together with its subsidiaries, the “Group”), a global digital operator that provides converged connectivity and online services, and its subsidiary VEON Holdings B.V. (the “Company”) refer to the announcement dated 21 December 2022 relating to the Company’s proposed scheme of arrangement (the “Scheme”) in respect of the 5.95% notes due February 2023 and 7.25% notes due April 2023 issued by the Company (together, the “2023 Notes”), and in particular relating to the convening of a single meeting of Scheme Creditors to be held on 24 January 2023 (the “Scheme Meeting”).

Key Points: 
  • Amsterdam, Netherlands, 11 January 2023 23:50 CET: VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON) (“VEON” or, together with its subsidiaries, the “Group”), a global digital operator that provides converged connectivity and online services, and its subsidiary VEON Holdings B.V. (the “Company”) refer to the announcement dated 21 December 2022 relating to the Company’s proposed scheme of arrangement (the “Scheme”) in respect of the 5.95% notes due February 2023 and 7.25% notes due April 2023 issued by the Company (together, the “2023 Notes”), and in particular relating to the convening of a single meeting of Scheme Creditors to be held on 24 January 2023 (the “Scheme Meeting”).
  • The Company has today issued an amended Explanatory Statement in connection with the Scheme, which amends the terms of the Scheme (the “Amended Explanatory Statement”).
  • Following feedback from certain of the 2023 Noteholders, the Company has today informed the Scheme Creditors, by the Amended Explanatory Statement, that it has amended the terms of the proposal set out in the Scheme.
  • Scheme Creditors or, if a corporation, their representative, or the proxy attending the Scheme Meeting on their behalf will be required to verify their entitlement to attend the Scheme Meeting as a Scheme Creditor before they will be granted access to the Scheme Meeting by a representative of the Information Agent.

Amryt Announces Details of EMA Contingent Value Rights Payment

Retrieved on: 
Tuesday, May 17, 2022
Deed poll, USD, Loan note, CHMP, EMA, Diet, Lipodystrophy, EB, Investment, Degenerative disease, Birth, European, COVID-19, Lomitapide, Octreotide, Link group, GL, Acquisition, Company, Holder, European Medicines Agency, Deed, Lists of diseases, Somatostatin, Nasdaq, Environment, Patient, Acromegaly, Metreleptin, Forward-looking statement, Contingent value rights, Pharmaceutical industry, Security (finance), Dietary supplement, Junctional epidermolysis bullosa (medicine), EU

Each CVR Holder will be issued with one loan note of USD$0.0995 for each CVR they hold (each a Loan Note).

Key Points: 
  • Each CVR Holder will be issued with one loan note of USD$0.0995 for each CVR they hold (each a Loan Note).
  • The total amount due to each CVR Holder will be paid by cheque on the Payment Date.
  • Amryt alsointends to develop oral medications that are currently only available as injectable therapies through itsTransient PermeabilityEnhancer (TPE) technology platform.For more information on Amryt, including products, please visit www.amrytpharma.com .
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.